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Abstract 
Asthma and COPD make up the majority of obstructive airways diseases (OADs), which 
affects ~11% of the population. The main drugs used to treat OADs have not changed in the 
past five decades, with advancements mainly comprising variations on existing treatments. 
The recent biologics are beneficial to only specific subsets of patients. Part of this may lie in 
our inability to adequately characterise the tremendous heterogeneity in every aspect of 
OAD. The field is currently moving towards the concept of personalised medicine, based on 
a focus on treatable traits that are objective, measurable and modifiable. We propose 
extending this concept via the use of emerging clinical tools for comprehensive physiological 
phenotyping. We describe, based on published data, the evidence for the use of functional 
imaging, gas washout techniques and oscillometry, as well as potential future applications, 
to more comprehensively assess and predict treatment response in OADs. In this way, we 
hope to demonstrate how physiological phenotyping tools will improve the way in which 
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Introduction 
Asthma and COPD make up the majority of obstructive airways diseases (OADs) and airflow 
obstruction is present in around 11% of the population(1) (defined by the older criterion of 
post-bronchodilator FEV1/FVC ratio of 0.70, prior to the introduction of new criteria(2)). The 
annual cost of asthma alone to the Australian economy in over 2 million asthmatic sufferers 
is nearly $AUD30M. The clinical expression of both asthma and chronic obstructive 
pulmonary disease (COPD) are highly variable and heterogeneous, as well as the responses 
to treatment. The histopathology of asthma and COPD also differ markedly, although there 
is overlap in clinical and pathophysiologic features e.g. alveolar enlargement(3) (4), loss of 
lung elasticity(5, 6), inflammation(7) and bronchodilator responsiveness(8).  
 
Until the recent developments on biological treatments in asthma and COPD, the main 
drugs used to treat OADs have not changed since the introductions of salbutamol in 1969, 
the inhaled corticosteroid (ICS) beclomethasone in 1972 (9), and ipratropium in 1974.  
Better versions have arrived but the ‘new treatment paradigms’ for OADs are just varying 
combinations of long acting versions of those three basic drugs, e.g. dual long acting β2-
agonist (LABA) / long acting muscarinic antagonist (LAMA) vs ICS containing formulations in 
COPD, and regular vs as needed (PRN) ICS in asthma. The clinical trials to test efficacy of 
these variations required thousands of subjects to be enrolled in each trial. The large 
numbers are due to the high degree of heterogeneity in the underlying pathophysiologic 
processes of the study populations. It is highly unlikely that there will be any further 
‘development’ of those 3 drug classes given that there are once-daily preparations of highly 
potent formulations, of low systemic activity, delivered to the lungs by highly efficient 
aerosol delivery devices. The problem remains that we (clinicians and researchers) have not 
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defined airways diseases in sufficient depth, to allow development of new drugs to proceed 
with any confidence; medications with specific targets may work for some but not others 
(biologics being a case in point), due to the wide heterogeneity in the disease population.  
 
Physiological Phenotyping and Treatable Traits 
OADs are traditionally given disease labels (diagnoses). The Global Initiative for Asthma 
defines asthma as a heterogeneous disease often associated with chronic airway 
inflammation in which symptoms and airflow obstruction vary over time(10). The Global 
Initiative for COPD defines COPD as persistent respiratory symptoms and airflow limitation 
caused by inhalation of noxious particles/gases(11). It is associated with airway and/or 
alveolar abnormalities. We note with particular interest that variability in both symptoms 
and lung function are a key distinguishing feature between asthma and COPD.  In practice, 
diagnosis of OADs are done predominantly by symptoms alone and by response to 
treatment, both of which perform poorly since neither are sensitive nor specific, and can 
suffer from poor subjective perception or recall bias. Furthermore, many patients’ symptom 
perception is not in proportion to their underlying disease severity(12). The gold standard 
measurement of airflow obstruction, spirometry, is infrequently done and abnormal 
spirometry can occur due to a variety of pathophysiological processes, which also makes it 
non-specific for OAD diagnosis. Therefore, the definitions by which labels are given are 
problematic. A common definition of asthma for clinical trials and epidemiological studies is 
a past doctor diagnosis of asthma and respiratory symptoms in the absence of significant 
smoking history, with or without bronchodilator reversibility.  A common definition of COPD 
is respiratory symptoms, smoking history and obstructed spirometry, in the absence of any 
doctor diagnosis of asthma. However, the ‘Dutch hypothesis’ arose from Orie et al(13, 14) in 
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which asthma, bronchitis and COPD were considered a continuum of airways disease, rather 
than being considered as separate entities. Within this paradigm, genetic predisposition 
(family history and genetic associations), early life exposures (e.g. maternal smoking and 
infections), airway hyperresponsiveness, allergy, airway narrowing, reversibility in response 
to treatment, day-to-day variability and inflammatory phenotype, all play a part in the 
manifestation of disease, regardless of whether it is asthma or COPD. This inherently 
suggests that OADs should be characterised extensively in a clinical and pathophysiologic 
sense. 
 
Although this concept is not yet commonplace in clinical practice, there is increasing 
appreciation in the field for the idea of label-free diagnosis(15), with an emphasis on 
treatable traits, i.e. those that can be modified by treatment(16), biomarkers and 
consequently ‘precision’ or ‘tailored’ therapy, rather than disease labelling. The ultimate 
ambition of this approach is the determination of endotypes of OAD, in which specific 
pathways are identified that control the disease and can be targeted to resolve the clinical 
manifestations(17). Compare this with other common diseases, such as coronary heart 
disease, hypertension and diabetes, where despite having different underlying causes and 
clinical significances in individuals, the focus is instead on treatment on the basis of 
measurable biomarkers(16). In the same way, we argue that OAD requires a similar 
approach, rather than just based on disease labels (diagnoses) such as asthma and COPD. 
While this goal has yet to be realised in respiratory medicine, the discovery of molecular 
phenotypes and associated inflammatory markers has successfully driven recent drug 
development such as the new biological treatments(18, 19). A recent example is the 
realisation that blood eosinophilia identifies an asthma phenotype that may respond to anti-
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IL5 targeted treatment. The individual response rate at the outset of such treatment may 
vary although there is a mean group benefit. Furthermore, the definition of response is 
debated but often relates to patient reported outcomes rather than an objective marker of 
the underlying disease being treated.  
 
We propose that physiological phenotyping can take us further, enabling us to better take 
into account the heterogeneous origins and pathophysiological mechanisms of OADs, and 
consequently better characterise responses to treatment, in the form of physiologically 
defined treatable traits. Some of these concepts are already known and already in use in 
clinical practice to varying extents, e.g. peak flow variability and airway 
hyperresponsiveness.  
   
Physiological Phenotyping: What Tools are Available? 
The tools that are useful for physiological phenotyping take into account the underlying 
anatomy and physiology of the lung. The lung is an asymmetrically shaped organ, with an 
elastic alveolar component supplied by asymmetrically bifurcating airways which have a 
mechanical compliance that is matched to alveolar compliance. This anatomical structure 
leads to ventilation being somewhat uneven (ventilation heterogeneity) and with increasing 
age, ventilation reduces and even ceases in the basal portions of the lung (airway closure), 
while in non-basal zones, ventilation becomes more heterogeneous. Phenotyping tools 
ideally also allow us to measure the function of the large and small airways. This is 
important because spirometry is insensitive to small airway function, yet this is the site 
where early abnormalities are thought to manifest(20). 
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Functional imaging allows measurement of ventilation heterogeneity.  Computed 
Tomography (CT) is easily accessible and relatively cheap, and its most clinically relevant use 
is in measuring lung density (emphysema, gas trapping), providing a measure of extent and 
distribution.  Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and 
Single Photon Emission Computed Tomography (SPECT) are imaging techniques that provide 
measurements of ventilation distribution. They have been used extensively in research and 
will likely be used routinely in the clinical assessment of OAD in future, but require further 
research to achieve this.  
 
Lung function techniques that reflect ventilation heterogeneity include inert gas washout 
techniques, especially the multiple breath washout (MBW) technique. Recent 
standardisation work, across both paediatrics and adult testing(21, 22), has resulted in 
validated commercial equipment(23, 24), and increased interest in use in clinical care.  The 
technique may utilise an exogenous inert gas (e.g. sulphur hexafluoride (SF6), helium or 
argon) which is inhaled in low concentration until steady state is reached within the lungs 
(wash-in). Once the inspired inert gas is removed, the subject then breathes room air to 
‘wash out’ the gas from the lungs and the pattern of the inert gas concentration change 
during each breath, as the inert gas is progressively washed out of the lungs by normal 
breathing, provides information on the severity of ventilation heterogeneity (25). An 
alternative method is to utilise the nitrogen that is resident in the lungs (nitrogen washout 
test or resident gas technique). A nitrogen (N2) inert gas washout test does not require an 
initial wash-in phase as the gas of interest is already resident within the lungs. During 
washout 100% oxygen washes N2 out of the lungs. Since ventilation distribution is 
determined predominantly at the small airway level, MBW reflect heterogeneity of function 
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in the small airway compartment. Advances in technology will provide potentially more 
clinically useful parameters from this technique(26).  
 
The forced oscillation technique (FOT), also known as oscillometry, is another method, 
which measures the mechanical properties of the respiratory system (lungs and upper and 
lower airways), based on the response to oscillatory pressure or flow stimuli, usually applied 
at the mouth and during quiet, tidal breathing. The response of the respiratory system is 
measured by the input impedance, i.e. the ratio between pressure and airflow oscillations at 
the mouth. This in turn can be partitioned into the mechanical parameters resistance (the 
flow-dependent component of impedance, which primarily reflects airway calibre) and 
reactance (the volume-dependent component, which primarily reflects elasticity of the 
respiratory system). Thus, both oscillatory resistance and reactance have a physiologic basis 
that suggests that they should be physiologically informative in OAD.  Oscillations of 
multiple frequencies can be delivered simultaneously, with typical frequencies used being 5, 
11 and 19 Hz. This is important because different parts of the lung respond to different 
frequencies – while resistance and reactance at 5 Hz reflect the mechanical properties of 
the airway tree, the influence of the small airways and peripheral lung diminish with 
increasing frequency. The frequency dependence of resistance between 5 to 19 Hz has been 
shown to reflect heterogeneity in the distribution of airway narrowing and/or closure across 
the airway tree(27-29). Furthermore, it is possible to track changes in resistance and 
reactance within a breathing cycle, which can be useful to non-invasively detect expiratory 
flow limitation during breathing(30).  
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Armed with these tools, physiological phenotypes may not only help us provide better 
insight into the causal mechanisms of disease, they may also help us assess interventions, 
e.g. bronchodilator responsiveness measured by FOT and MBW measurements of 
ventilation heterogeneity could be helpful in identifying patients that respond to 
bronchodilator or inhaled corticosteroid treatment, or provide more comprehensive 
markers of response to both existing and new treatments for OAD.  Monitoring of disease 
activity i.e. progression of airflow obstruction, changes in day-to-day variability of airway 
calibre (that characterises asthma), risk of exacerbations or attacks, early detection of those 
at risk of disease progression (e.g. rate of loss of FEV1) are just some examples of how 
physiologic phenotyping, when combined with cellular and genetic markers of disease, can 
provide the necessary information to advance the understanding and management of OADs.  
 
Current Evidence for Clinical Utility 
Here we describe, based on published data, the evidence for the use of functional imaging, 
MBW and FOT to better assess and predict treatment response in OADs. In this way, we 
hope to demonstrate how physiological phenotyping tools will improve the way in which 





MBW is of particular interest in paediatrics due to its high feasibility as a tidal breathing 
technique: >80% feasibility reported in infancy and preschool age ranges and >90% above 
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that age range(31). The OAD where MBW is closest to integration into clinical care is Cystic 
Fibrosis (CF): greater sensitivity to detect early OAD vs spirometry has been shown across all 
ages(31), with progression over time(32), and exciting ability to detect the beneficial effects 
of intervention(33, 34). These beneficial effects of intervention can be detected in far 
smaller numbers than required for spirometry(33, 35), and its main outcome Lung Clearance 
Index (LCI) has been formally endorsed as a primary outcome for research studies(36). This 
has led to the first successful implementation of LCI as a primary outcome measure in large 
pharmaceutical sponsored multicentre international studies(37) using a structured 
approach to training, certification and quality control of MBW data(38).  
 
Asthma and wheeze 
MBW utility in paediatric asthma is less well defined but emerging(39). Histological changes 
in early asthma have been demonstrated in endobronchial biopsies in recurrent wheezers 
during the preschool years (e.g. higher reticular basement membrane thickness and 
mucosal eosinophilia), and were not only associated with higher ventilation inhomogeneity, 
but also later early school age recognised markers of asthma (exhaled nitric oxide 
levels)(40). LCI is increased in school aged asthmatic subjects, compared to healthy 
controls(41), is related to AHR(42) and is higher in those with poor asthma control(43).  
Increased ventilation inhomogeneity is still detectable in well controlled asthmatics after 
SABA administration(44, 45). Advanced analysis of the  change in phase III slope throughout 
MBW suggests a pattern of abnormality in the conducting airways rather than acinar airway 
abnormality in paediatric asthma(42-45).  
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The utility of oscillometry in paediatric asthma has also been of long standing interest due 
to its high feasibility as a tidal breathing test in young children(46). Diagnostic utility of 
conventional FOT methodologies (i.e. mean values of resistance and reactance over a 
recording period) in children with asthma appear limited(47, 48). FOT parameters 
objectively measure bronchodilator response(49, 50) and airways hyperresponsiveness(51, 
52). However, within-breath differences in FOT parameters appear to hold additional utility 
to conventional mean measurements across the monitoring period. Czovek and colleagues 
examined utility in preschool subjects with acute and recurrent wheeze(53). The change 
between end-inspiratory and end-expiratory resistance detected airway obstruction with 
high sensitivity and specificity (92% and 89%, respectively) in the acute wheeze setting, and 
was able to distinguish children with recurrent wheeze from healthy children with high 
sensitivity.    
 
Adult Utility 
It should be noted that the role of spirometry as a diagnostic test of airway function for 
OADs in adults is, in itself, bona fide physiological phenotyping. The accuracy and ability to 
perform spirometry repeatedly meant the test could be used as an important endpoint in 
multicentre clinical trials to document efficacy of therapeutic targets. Nevertheless, a 
monolithic view of airway function that can only be assessed by spirometry, has resulted in 
a respiratory community that has struggled to grapple with the complexity of airway 
physiology and the heterogeneous nature of OADs.  
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COPD 
This can be appreciated in the approach to COPD where the condition is defined by 
abnormal spirometry. Yet, clinicians have long appreciated the importance of emphysema 
observed in some patients that have normal spirometry and another group of patients that 
seem to have ‘early’ lung disease or ‘at risk’ of developing COPD. Here, guidelines have 
variably introduced (and removed) new categories to define these patient groups such as 
“Stage 0” in the 2001 GOLD publication that was subsequently removed(54, 55).  
 
Large observational cohort studies such as Spiromics and COPDGene have contributed to 
renewed interest in understanding ‘early’ COPD, especially in smokers who have preserved 
FEV1/FVC ratio who may progress towards obstruction. Significant effort has been made to 
identify molecular signatures to identify these patients but along the way this has led to 
greater appreciation of abnormalities in imaging and lung function that can also be 
assessed. Previous work from our group in such ‘smokers with normal spirometry’ found 
abnormalities were frequently detected in peripheral airway function whether measured 
with MBW or oscillometry(56). Interestingly, most patients displayed an abnormality in one 
but not both peripheral lung function modalities highlighting, yet again, the importance of a 
multifaceted approach to physiologically phenotyping patients using a variety of tests. 
 
Oscillometry is now an established clinical lung function test with commercial devices 
increasingly available and the recent publication of a standards document to guide its 
implementation into a clinical laboratory(57). Just as is the case in paediatrics, it has the 
appeal of being a relatively effort independent test and, hence, is perfectly suited for 
monitoring patients with very severe disease or the very old. In a pilot study of people with 
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COPD, Milne et al(58) found a correlation between baseline oscillometry and the 
subsequent improvement in gas trapping following the inhalation of a long acting beta-
agonist. Indeed, subsequent work confirmed that oscillometry in COPD measures those 
areas of lung that are participating in ventilation (and hence likely to respond to an inhaled 
medication) (59). Thus, oscillometry may serve as a useful predictor of specific therapeutic 
interventions. In contrast, current COPD guidelines are heavily focussed on symptoms, and 
evaluation of a long acting bronchodilator in an individual patient involves switching or 
adding another therapeutic class if the symptomatic response is deemed less than optimum. 
 
Asthma 
The importance of small airways disease in asthma is now established. Here, therapeutics 
have sought to optimise delivery to the periphery of the lung with mixed success (60). The 
importance of having the correct tools to assess such intervention is once again highlighted. 
For example, the presence of a bronchodilator response measured with oscillometry 
identifies more patients with poorly controlled asthma compared to spirometry(61). 
Meanwhile, MBW indices improve with treatment, both in mild-to-moderate(62) as well as 
severe uncontrolled asthma(63). In severe eosinophilic asthma, we recently reported on the 
early improvement in MBW indices after the commencement of anti-IL5 treatment(64). 
Importantly, improvement in these indices correlates with symptom improvements and may 
be a predictor of a more sustained symptomatic response. In mild-to-moderate asthma, 
MBW indices predicted symptomatic response to ICS titration, with greater apparent 
sensitivity than exhaled nitric oxide (FeNO), whereas FEV1 did not(65). In severe 
uncontrolled asthma, both MBW and oscillometry predicted improvements with high dose 
ICS, again where FEV1 did not(63).  Both MBW and oscilllometry have been studied 
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extensively in asthma but often in smaller single centre studies. The recent publication of 
the multinational ATLANTIS study is the first to bridge this gap reporting on the role of such 
tests in assessing the different phenotypes in asthma(66).  
 
In terms of imaging, MRI-based ventilation defect measures relate to asthma symptoms and 
quality of life, independently to oscillometry(67). More importantly, they are normalised by 
biologic treatment in asthma(68). 
 
Other diseases and co-morbidities 
In addition to applications in smokers, COPD and asthma, MBW and oscillometry have also 
been shown to be a sensitive measure of small airway function in bronchiolitis obliterans in 
haemopoietic stem cell recipients(69), and airway dysfunction in obesity(70). Similarly, 
ventilation imaging has also provided important insights into the respiratory effects of 
obesity(71), as well as in detection of early lung disease in cystic fibrosis(72).  
 
Physiological phenotyping: some pitfalls  
If these novel physiological tools are now available, and if the body of recent clinical studies 
suggest that they have consistent and strong clinical associations, then why has there been 
little or slow uptake into respiratory medicine practice? Why have we not moved forward 
from conventional spirometry?  
Structure-function relationships in pathology 
A potential reason may be the lack of strong or consistent structure-function correlations 
with histopathological measures. For example, reticular basement membrane thickness 
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does not correlate with ventilation heterogeneity measured by inert gas washout in 
paediatric patients with asthma or severe wheeze(40, 73). In contrast, increased ventilation 
heterogeneity in patients with CF correlated with reticular basement membrane thickness 
and HRCT scores of abnormal lung structure(73, 74). There is circumstantial evidence that 
oscillometry is sensitive to airway remodelling in asthma, since the relationship between 
lung volume and respiratory system conductance (reciprocal of resistance) does not 
normalise following bronchodilator administration(75). In terms of inflammation, ventilation 
heterogeneity in diffusion-dependent airways (i.e. acinar airways) correlated with sputum 
neutrophils whereas heterogeneity in convection-dependent airways (i.e. conducting 
airways) correlated with sputum eosinophils(76). 
 
The mixed evidence is perhaps not surprising since these tests of lung mechanics and 
ventilation heterogeneity by their nature measure the summative process of many 
pathological abnormalities, rather than individual cellular interactions. ASM contraction, 
airway thickening due to inflammation, as well as structural remodelling of the ASM, sub-
epithelial layer, reticular basement membrane or epithelial layer, can all contribute to an 
overall increase in airway resistance. Similarly, changes in alveolar size, loss of alveolar septa 
or changes in surfactant function would all contribute in varying extents to reduced lung 
compliance. All of these in turn would contribute to changes in ventilation distribution. 
Given this complexity, it is difficult to directly and specifically infer the pathology underlying 
some of these physiologic measures. 
 
On the other hand, functional imaging may disentangle the individual contributions of 
different pathological processes. Recent development of a complex image registration 
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technique called Parametric Response Mapping (PRM) allows comparison of lung density on 
CT between functional residual capacity and total lung capacity in order to distinguish small 
airways disease from emphysema(77). Importantly, a post-mortem study recently provided 
much needed pathological verification of PRM, reporting that PRM small airway function 
corresponded to abnormal terminal bronchial pathology, while PRM emphysema 
corresponded to alveolar enlargement(78). Ventilation measures from MRI also show 
similar promise; extent of non-ventilated lung volume correlates with eosinophilic 
inflammation in sputum and mucus plugs and, may also reflect airway tone(79). Finally, the 
recent development and validation of optical coherence technology (OCT), which allows 
quantification of airway wall layers, may provide a sensitive and comparatively non-invasive 
method to measure multiple lung sites for each individual(80, 81). A combination of OCT 
and ventilation imaging may be able to further link specific structural changes with 
physiological phenotypes of OAD and thereby promote localised and pathology-guided 
intervention. 
 
Moving beyond spirometry? 
Despite its own lack of validation in structure-function studies, spirometry has been and will 
likely remain a cornerstone of respiratory measurement. It has the advantage of being 
simpler in principle to understand and explain, even though it difficult to perform in some. 
In contrast, the tests described in this paper are complex in underlying principles and 
require good knowledge of underlying basic pulmonary physiology and skill in teaching by 
experts. Whilst the feasibility to train operators across a large number of sites within 
international research studies with techniques such as these has been demonstrated(82), 
 17  
and provides insight into what infrastructure may be required for widespread clinical 
implementation(38), this has not been done to date. This and the lack of guideline 
recommendations on how to utilise these tests to improve clinical outcomes are the final 
hurdles before widespread clinical implementation. Future studies assessing and predicting 
response to treatment, outcome risks and monitoring, and especially determining 
magnitude of clinically meaningful changes remain areas of urgently needed research. Also, 
the most appropriate test choice will likely differ according to clinical scenario. For example, 
inert gas washout may be sensitive to detect change in subjects with CF or bronchiolitis 
obliterans syndrome, whereas oscillometry may offer greater insight in asthma or COPD.  
 
Emerging Applications 
Lung volume dependence 
There is growing evidence that physiological measurements that encompass the entire lung 
volume range may provide clinically meaningful insight into OAD. As described above, 
imaging methods such as PRM examine changes in lung density over excursions in lung 
volume to provide insight into small airways disease and emphysema.  While PRM has 
predominantly been measured in COPD, recent evidence that it correlates with asthma 
control and quality of life suggests it also has clinical utility in asthma (83). Similarly, 
extending MBW through multiple inspiratory capacity manoeuvres after inert gas 
concentrations fall below 2% allows calculation of the volume of trapped gas at functional 
residual capacity(84). Similarly, the non-linear relationship between lung volume and 
reactance is thought to indicate the volume at which airway closure begins since it 
correlates with predicted closing capacity in people without lung disease(85). The reactance 
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measured at the onset of airway closure is an independent predictor of asthma control(86), 
suggesting that it reflects important clinical information not detected by traditional lung 
function. Since airway closure and gas trapping are well-recognised markers of severe 
disease, the measurement of early airway closure and gas trapping provides attractive 
measures for phenotyping OADs. 
 
Home monitoring and day-to-day variability 
The simplicity and ease of oscillometry lends itself to frequent/daily monitoring particularly 
in the home where unsupervised spirometry or peak flow measurements remain 
challenging. Technological advances now allows measurements to be sent over (wireless) 
internet networks increasing its usefulness in telemedicine. Feasibility has been 
demonstrated in both children under parental supervision(87), adults with asthma(88) and 
elderly people with COPD(89). A recent large trial suggested an improvement in re-
hospitalisation rates with home monitoring using oscillometry compared to usual care in 
COPD patients with a previous exacerbation(90).   
 
Day-to-day variability appears to offer exciting insight into the variable airflow obstruction 
that characterises asthma. In children, day-to-day variability in resistance or reactance is 
increased in those with poor asthma control, and missed by peak flow monitoring(91). 
Home telemonitoring over longer term (months) reveal patterns of increased day-to-day 
variability prior to an exacerbation in both asthma(87) as well as COPD(92), suggesting 
utility in detecting onset of exacerbation.  
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Furthermore, there is promise in the use of advanced analysis techniques to better capture 
this day-to-day variability in lung function. Specific patterns in lung function over time have 
been shown to occur naturally and altered as a result of pathology, as well as in response to 
stimuli or treatment(93). Day-to-day patterns in peak expiratory flow are different between 
health and asthma(94), and are altered and predict response to treatment in asthma(95, 96) 
(97). These patterns also relate to asthma control(98), and could be used to predict future 
risk of exacerbations(99). Combining these approaches with oscillometry has the potential 
to further increase sensitivity in predicting exacerbations(100).  
 
As these new methodologies mature, their application to lung function variability could 
open a new era of research in OAD. First, having an objective marker for detecting 
exacerbation onset, perhaps earlier than symptoms, may provide novel targets for 
pharmacological developments, since it is likely that the initial immune response during an 
exacerbation is significantly different to when symptoms are present. Second, the ability to 
predict exacerbations in a more timely manner (e.g. days or weeks versus the current best 
predictor of a previous exacerbation in the past 12 months) may provide the opportunity to 
develop medications with differing timing/dynamics of action, perhaps instigating a change 
in the way we currently treat exacerbations.  
 
Complex system approaches 
While these physiological tools offer superior objectivity and sensitivity to symptoms and 
conventional lung function, separately they still represent only specific aspects of a larger, 
more complex picture. The lung in health and disease comprises an essentially complex 
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system, which may not be captured by single, simple biomarkers. A complex system has 
multiple components all interacting with one another, and exhibits nonlinearities in 
structure and function, often resulting in deterministic patterns in measureable markers 
over time(93, 101). Thus, truly comprehensive disease phenotyping should take these 
complex behaviours into account, and include physiological as well as genetic, molecular 
and cellular measures, in addition to patient-based measures such as obesity, adherence, 
symptom perception, etc (Figure 1).  Meanwhile, physiological treatable traits themselves 
could be visualised as the numerous spokes on a hypothetical wheel (Figure 2). Physiological 
phenotypes of airways disease could then be described based on the different extents of 
abnormality along the different spokes, including different variability over time (indicated 
by the dotted profile). Treatment targeting each physiological trait (or clusters/networks of 
traits) then aims to reduce these abnormalities to a physiological profile that is more similar 
to health. In this way physiological phenotyping would contribute to a label-free, treatable 
traits, approach to the management of OADs.  
 
Conclusions 
Patient-reported outcomes are important diagnosis tools and endpoints in chronic disease 
such as OADs, and some may argue that research into drug development should focus 
entirely on symptoms as the endpoint of interest. However, they are by nature subjective, 
and the physiological processes that contribute to symptoms can be varied. A purely 
symptom-based approach would be detrimental to future therapeutic developments and 
eventually patient care will suffer. We are now already moving towards the concept of 
personalised medicine, based on a focus on treatable traits that are objective, measurable 
and modifiable. We propose extending this concept via the use of emerging clinical tools for 
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measuring lung structure and function, to identify physiological phenotypes and their ability 
to assess and predict response to treatment. Characterising the physiological characteristics 
of OAD is clinically useful and will facilitate drug development for OAD, and enable us to 
account for the tremendous heterogeneity seen in OADs. Furthermore, advances can only 
be achieved if the complexity of the disease (and patient) is assessed across a number of 
platforms including lung function, imaging, biomarkers and genetic information where 
available. This comprehensive approach will enable us to better tailor interventions to the 
patients that will benefit the most from specific therapeutics. 
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FIGURES 
 
Figure 1. Comprehensive phenotyping of airways disease should take into account 
physiological as well as genetic, molecular and cellular measures, in addition to patient-
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Figure 2. Possible physiological treatable traits. Different airways disease phenotypes can 
manifest as different profiles, with different extents of abnormality along the different 
spokes, including different variability over time (indicated by the dotted profile).  
 
 
